# Parabilis Medicines, Inc. (PBLS)

> Source: Nexqual · https://nexqual.com/PBLS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Parabilis Medicines, Inc. (PBLS), nexqual.com/PBLS" · informational, not investment advice.

**Price:** USD 26.92 (-3.34% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 27.85 · day 26.58–28.29 · 52w 22.66–42.49 · market cap $3.33B · NMS

## Key facts
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $441M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 41.4 (range 40–45).
- Total return with dividends: 1Y -14.8% vs S&P 500 +14.9%; 5Y -1.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.38, revenue estimate $500K.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 3.2x · Earnings yield -5.14% · Net cash $1.11B · EV $2.21B

## Insider purchases (SEC Form 4, open-market, last ~7 months)
5 purchases, $441M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-20…2026-07-22 | Ra Capital Management, L.P. | Director | 244,593 | $6.9M | 28.29 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-12…2026-06-15 | Sebulsky Alan | Director | 17,500 | $474K | 27.06 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Levy Guy |  | 500,000 | $10.0M | 20 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Ra Capital Management, L.P. | Director | 21,188,750 | $424M | 20 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Sebulsky Alan | Director | 12,500 | $250K | 20 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 41.4 (low 40, high 45).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | HC Wainwright & Co. | Initiated | Buy | $40 |
| 2026-07-06 | Guggenheim | Initiated | Buy | $40 |
| 2026-07-06 | Leerink Partners | Initiated | Outperform | $40 |
| 2026-07-06 | B of A Securities | Initiated | Buy | $45 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-06-10) | 5Y (from 2026-06-08) |
|---|---|---|
| Total return | -14.8% | -1.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 74.1% | 77.4% |
| Max drawdown | -45.5% (Sep 2026→Oct 2026) | -45.5% (Sep 2026→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/PBLS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-13)

- "The Company's cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund its operations into 2030."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.38 | $0.00 | — | $500,000 | 3 |
| Next quarter (ends 2026-12-31) | $-0.40 | $0.00 | — | $1.0M | 3 |
| Current fiscal year (ends 2026-12-31) | $-2.58 | $0.00 | — | $1.2M | 3 |
| Next fiscal year (ends 2027-12-31) | $-2.19 | $0.00 | — | $4.8M | 3 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-12): ±24.2%; last 1 reports averaged ±0.9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 76.4% | ±24.2% |
| 2027-02-19 | 119 | 74.0% | ±36.4% |
| 2027-05-21 | 210 | 72.5% | ±44.6% |